Literature DB >> 25680886

Contextual niche signals towards colorectal tumor progression by mesenchymal stem cell in the mouse xenograft model.

Suguru Nakagaki1, Yoshiaki Arimura, Kanna Nagaishi, Hiroyuki Isshiki, Masanao Nasuno, Shuhei Watanabe, Masashi Idogawa, Kentaro Yamashita, Yasuyoshi Naishiro, Yasushi Adachi, Hiromu Suzuki, Mineko Fujimiya, Kohzoh Imai, Yasuhisa Shinomura.   

Abstract

BACKGROUND: The role of mesenchymal stem/stromal cells (MSCs) in tumorigenesis remains controversial. This study aimed to determine whether heterotypic interactions between MSCs and colon cancer cells can supply contextual signals towards tumor progression.
METHODS: Xenografts consisting of co-implanted human colorectal cancer cells with rat MSCs in immunodeficient mice were evaluated by tumor progression, angiogenic profiles, and MSC fate. Furthermore, we investigated how MSCs function as a cancer cell niche by co-culture experiments in vitro.
RESULTS: Tumor growth progressed in two ways, either independent of or dependent on MSCs. Such cell line-specific dependency could not be explained by host immune competency. COLO 320 xenograft angiogenesis was MSC-dependent, but less dependent on vascular endothelial growth factor (VEGF), whereas HT-29 angiogenesis was not MSC-dependent, but was VEGF-dependent. MSCs and COLO 320 cells established a functional positive feedback loop that triggered formation of a cancer cell niche, leading to AKT activation. Subsequently, MSCs differentiated into pericytes that enhanced angiogenesis as a perivascular niche. In contrast, the MSC niche conferred an anti-proliferative property to HT-29 cells, through mesenchymal-epithelial transition resulting in p38 activation.
CONCLUSIONS: In conclusion, MSCs demonstrate pleiotropic capabilities as a cancer cell or perivascular niche to modulate colorectal cancer cell fate in a cell line-dependent manner in a xenogeneic context.

Entities:  

Mesh:

Year:  2015        PMID: 25680886     DOI: 10.1007/s00535-015-1049-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  32 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Rat marrow stromal cells are more sensitive to plating density and expand more rapidly from single-cell-derived colonies than human marrow stromal cells.

Authors:  E H Javazon; D C Colter; E J Schwarz; D J Prockop
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

3.  Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.

Authors:  Astrid De Boeck; Patrick Pauwels; Karen Hensen; Jean-Luc Rummens; Wendy Westbroek; An Hendrix; Dawn Maynard; Hannelore Denys; Kathleen Lambein; Geert Braems; Christian Gespach; Marc Bracke; Olivier De Wever
Journal:  Gut       Date:  2012-04-25       Impact factor: 23.059

4.  Mesenchymal stem cells enhance growth and metastasis of colon cancer.

Authors:  Kei Shinagawa; Yasuhiko Kitadai; Miwako Tanaka; Tomonori Sumida; Michiyo Kodama; Yukihito Higashi; Shinji Tanaka; Wataru Yasui; Kazuaki Chayama
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

5.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

6.  Mesenchymal stem cells cancel azoxymethane-induced tumor initiation.

Authors:  Masanao Nasuno; Yoshiaki Arimura; Kanna Nagaishi; Hiroyuki Isshiki; Kei Onodera; Suguru Nakagaki; Shuhei Watanabe; Masashi Idogawa; Kentaro Yamashita; Yasuyoshi Naishiro; Yasushi Adachi; Hiromu Suzuki; Mineko Fujimiya; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

7.  Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer.

Authors:  Yan Liu; Zhi-peng Han; Shan-shan Zhang; Ying-ying Jing; Xin-xin Bu; Chen-yang Wang; Kai Sun; Guo-cheng Jiang; Xue Zhao; Rong Li; Lu Gao; Qiu-dong Zhao; Meng-chao Wu; Li-xin Wei
Journal:  J Biol Chem       Date:  2011-05-18       Impact factor: 5.157

8.  Characterization of quantitative mucin variants from a human colon cancer cell line.

Authors:  S F Kuan; J C Byrd; C B Basbaum; Y S Kim
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

9.  Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma.

Authors:  Aarif Y Khakoo; Shibani Pati; Stasia A Anderson; William Reid; Mohamed F Elshal; Ilsa I Rovira; Ahn T Nguyen; Daniela Malide; Christian A Combs; Gentzon Hall; Jianhu Zhang; Mark Raffeld; Terry B Rogers; William Stetler-Stevenson; Joseph A Frank; Marvin Reitz; Toren Finkel
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

10.  Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-β.

Authors:  Valentina Mele; Manuele G Muraro; Diego Calabrese; Dennis Pfaff; Nunzia Amatruda; Francesca Amicarella; Brynn Kvinlaug; Chiara Bocelli-Tyndall; Ivan Martin; Therese J Resink; Michael Heberer; Daniel Oertli; Luigi Terracciano; Giulio C Spagnoli; Giandomenica Iezzi
Journal:  Int J Cancer       Date:  2014-01-30       Impact factor: 7.396

View more
  1 in total

1.  Transplantation of placenta-derived multipotent cells in rats with dimethylhydrazine-induced colon cancer decreases survival rate.

Authors:  Hanna Svitina; Inessa Skrypkina; Pavlo Areshkov; Vitaliy Kyryk; Tetiana Bukreieva; Pavlo Klymenko; Liudmyla Garmanchuk; Galyna Lobintseva; Volodymyr Shablii
Journal:  Oncol Lett       Date:  2018-02-08       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.